Iovance Biotherapeutics (IOVA) said Monday its drug Amtagvi led to a 48.8% objective response rate in a retrospective real-world study of 41 patients with skin cancer.
Patients treated earlier, after two or fewer prior therapies, saw a response rate of 60.9%, compared to 33.3% among those with three or more previous treatments, the company said.
All participants were treated at authorized centers under current US prescribing guidelines and received at least one follow-up physician assessment, Iovance said.
Shares of the company were up more than 4% in recent Monday premarket activity.
Price: 1.95, Change: +0.08, Percent Change: +4.28
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.